Acute Myeloid Leukemia Medical Services in China

Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. It disrupts normal hematopoiesis, leading to cytopenias—resulting in fatigue, recurrent infections, and bleeding tendencies—and carries significant morbidity if untreated. AML incidence rises with age, with median diagnosis occurring in the sixth decade; risk stratification relies on cytogenetic profiling (e.g., t(8;21), inv(16), FLT3-ITD, NPM1 mutations) and molecular testing to guide prognosis and therapeutic decisions. Standard induction therapy typically involves “7+3” chemotherapy (cytarabine plus an anthracycline), followed by consolidation—either high-dose cytarabine or allogeneic hematopoietic stem cell transplantation (allo-HSCT) for eligible high-risk patients. Emerging targeted agents—including FLT3 inhibitors (gilteritinib), IDH1/2 inhibitors (ivosidenib, enasidenib), and venetoclax-based regimens—have improved outcomes, particularly in older or unfit individuals.

China offers compelling advantages for AML management: its top-tier oncology centers—such as Peking University People’s Hospital and Shanghai Ruijin Hospital—house nationally recognized leukemia research programs and perform over 2,000 allo-HSCT procedures annually, with 3-year overall survival rates exceeding 60% for intermediate-risk AML—comparable to leading Western institutions. Advanced diagnostics (NGS panels, multiparameter flow cytometry, MRD monitoring via qPCR or digital PCR) are routinely integrated into clinical pathways. Treatment costs remain substantially lower than in the US or Western Europe—typically 40–60% less for comprehensive care including induction, consolidation, and transplant—without compromising protocol adherence or quality standards. As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying physician credentials, coordinating appointments at JCI-accredited hospitals, providing itemized, transparent pricing in advance, arranging visa support, interpreters, accommodation, and post-treatment follow-up—all tailored to individual clinical and logistical needs.

Treatment Options & Itemized Cost Breakdown: Acute Myeloid Leukemia (AML)

Non-Surgical/Medical Therapy

*Induction Chemotherapy (7+3 regimen)*

• •Eligibility: Fit adults ≤60 years, ECOG 0–2, adequate organ function
• •Cost Breakdown (USD):

- Daunorubicin (60 mg/m² × 3 days): $1,240 - Supportive care (IV antibiotics, G-CSF, transfusions): $2,900 - Daily lab monitoring (CBC, coagulation, electrolytes, LDH): $420 - Bone marrow aspiration/biopsy (day 14/28): $380

*Targeted Therapy (FLT3-mutated AML)*

• •Eligibility: FLT3-ITD or TKD mutation confirmed by NGS
• •Cost Breakdown (USD):

- Gilteritinib (120 mg/day): $6,800/month - NGS panel (FLT3, NPM1, CEBPA, TP53): $490

Procedural/Interventional Options

*Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)*

• •Eligibility: CR1 high-risk AML, age ≤65, HLA-matched donor (sibling or MUD), no active infection or severe comorbidity
• •Preoperative Workup (USD):

- Donor lymphocyte typing (HLA-A/B/C/DR/DQ): $650 - Cardiac echo + renal scintigraphy: $510

• •Procedure & Hospitalization (USD):

- Stem cell infusion + 30-day inpatient care: $18,900 - GVHD prophylaxis (tacrolimus + methotrexate): $1,260

Special/Complex Condition Management

• •Relapsed/Refractory AML: Venetoclax + azacitidine (3-month course): $12,400
• •AML with TP53 mutation: Hypomethylating agent + clinical trial enrollment (no drug cost; screening labs: $320)
• •CNS involvement: Intrathecal cytarabine × 4 doses + cranial MRI: $1,680

Quick Selection Guide

• •Age <60, fit, standard-risk: Induction chemo → $6,790 total
• •Age 60–65, FLT3-mutated: Gilteritinib + supportive care → $7,220/month, lower toxicity than chemo
• •High-risk cytogenetics (e.g., complex karyotype): Proceed to allo-HSCT in CR1 → $22,740 pre-transplant + $23,860 transplant = $46,600 total
• •Age >70 or significant comorbidities (COPD, CKD stage 3): Low-intensity therapy (azacitidine ± venetoclax) → $8,900–$12,400/month, prioritizes quality of life
• •Budget-constrained (<$5,000): Generic cytarabine + daunorubicin induction at public hospital tier-3A → $4,200, includes mandatory transfusion support and infection management